One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Pet Cancer Therapeutics Market

[ 英語タイトル ] Pet Cancer Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083119
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Elanco
- AdvaVet Inc.
- ELIAS Animal Health
- Virbac
- Boehringer Ingelheim GmbH (Merial)
- Morphogenesis Inc.
- Radiology Oncology Systems
- Regeneus Ltd
- VetDC Inc.
- IDvet

- Zoetis

[Report Description]

The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. According to the Veterinary Cancer Society, cancer was the leading cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats, in 2017. The most common cancers in cats are leukaemia and lymphoma. Cancer is found mostly in ageing animals, but some breeds have higher rates of cancer than others. In addition to the aforementioned factor, growing pet health awareness and rise in R&D initiatives regarding pet cancer management are expected to propel market growth over the forecast period. However, side effects caused by drugs used for the treatment of pet cancers, the reluctance of pet owners to put their pet animals under medication is expected to restrain the pet cancer therapeutics market.

Key Market Trends

Cancers in Dogs are Expected to Lead the Market

Dogs get cancer at about the same rate as humans, while cats get fewer cancers. Some breeds or families of dogs have a higher incidence for developing cancer at an earlier age, but in most cases, it’s a disease found in aging animals. As per the non-profit organization FETCH a Cure, an estimated 6 million dogs were diagnosed with cancer in year 2019 across the globe. This indicates that there is a rising need for cancer treatment in dogs, which is likely to boost the demand for cancer therapeutics.In addition, the growing pet health awareness and a rise in the R&D initiatives regarding pet cancer management are expected to propel the market growth, over the forecast period. For instance, in April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

North America Dominates the Pet Cancer Therapeutics Market

North America is expected to retain its significant market share, owing to factors, such as rising pet adoption and increasing per capita animal healthcare expenditure. In addition, the rise in the prevalence of various animal diseases and injuries has been identified as the major factor fueling market growth. Approximately, 90 million dogs are owned in the United States, as per reported by the American Pet Products Association (APPA). In addition, the data published by APPA, in 2019, stated that the total pet healthcare expenditure is estimated to be USD 75.38 billion by the end of the year, while the expenditure in 2018 was USD 72.56 billion. North America also emphasizes on establishing proper skills among veterinary practitioners. Hence, all these factors are driving the growth of the pet cancer therapeutics market in North America.

Competitive Landscape

The market players in the pet cancer therapeutics market are involving in various growth strategies such as collaborations, partnerships, agreements, mergers and acquisitions in order to enhance the market presence. For instance, In April 2019, Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics, pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats and in Jan 2018, Aratana Therapeutics was granted conditional approval for its canine osteosarcoma vaccine, live Listeria vector (AT-014), by the USDA's Center for Veterinary Biologics.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Advanced Technology Leading to Innovations in Animal Healthcare
4.2.2 Increasing Initiatives by the Governments and Animal Welfare Associations of Different Countries
4.2.3 High Prevalence of Cancer in Pets
4.3 Market Restraints
4.3.1 Side Effects Associated with Pet Cancer Therapy
4.3.2 Increasing Cost of Animal Testing and Veterinary Services
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Therapy
5.1.1 Chemotherapy
5.1.2 Radiation therapy
5.1.3 Immunotherapy
5.1.4 Other Therapies
5.2 By Animal
5.2.1 Dog
5.2.2 Cat
5.2.3 Other Animals
5.3 By Application
5.3.1 Lymphoma
5.3.2 Mast Cell Cancer
5.3.3 Melanoma
5.3.4 Mammary and Squamous Cell Cancer
5.3.5 Other Applications

5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Elanco
6.1.2 AdvaVet Inc.
6.1.3 ELIAS Animal Health
6.1.4 Virbac
6.1.5 Boehringer Ingelheim GmbH (Merial)
6.1.6 Morphogenesis Inc.
6.1.7 Radiology Oncology Systems
6.1.8 Regeneus Ltd
6.1.9 VetDC Inc.
6.1.10 IDvet

6.1.11 Zoetis




Recommended reports